Adaptive Biotechnologies Highlights New Data Showcasing the Clinical Utility of clonoSEQ® MRD Testing in Patients with Blood Cancers at the 64th ASH Annual Meeting

Written by Customer Service on December 10, 2022. Posted in Public Companies.

Multiple presentations reinforce clonoSEQ’s ability to provide valuable insights for treatment surveillance and clinical decision-making More than 30 clonoSEQ-related abstracts to be presented at the meeting SEATTLE, Dec. 10, 2022 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced new data demonstrating the strengths of Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay in measuring minimal residual disease (MRD) in blood cancer patients. The data are being presented at the 64th Annual Meeting of the American Society of Hematology (ASH) taking place December 10-13, 2022. MRD refers to the small number of cancer cells...

Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derived CAR T-cell Therapy at 2022 ASH Annual Meeting

Written by Customer Service on December 10, 2022. Posted in Public Companies.

FT819 Off-the-Shelf CAR T-cell Product Candidate Derived from Clonal Engineered Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus Interim Phase 1 Dose-escalation Data Indicate Favorable Safety Profile with Complete Responses in Heavily Pre-treated Patients with Aggressive Large B-cell Lymphoma SAN DIEGO, Dec. 10, 2022 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today presented interim clinical data from the dose-escalation stage of its ongoing Phase 1 study of FT819 for patients with relapsed / refractory B-cell lymphoma (r/r BCL) at the 64th American Society of Hematology Annual Meeting and Exposition. The landmark trial is the first-ever clinical investigation...

Traction Uranium Corp. Closes First Tranche of Private Placement

Written by Customer Service on December 10, 2022. Posted in Public Companies.

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Dec. 09, 2022 (GLOBE NEWSWIRE) — Traction Uranium Corp. (the “Company” or “Traction”) ‎(CSE: TRAC) (OTC: TRCTF) (FRA: Z1K) is pleased to announce that it has closed the first tranche of a non-brokered private placement (the “First Tranche Private Placement”) for aggregate gross proceeds of approximately C$2,513,105.00. The Company issued 7,180,300 flow-through units (each, a “Flow-Through Unit”) at a price of C$0.35 per Flow-Through Unit. Each Flow-Through Unit consists of one (1) common share (each, a “FT Share”) and one half (1/2) common share purchase warrant (each, a “FT Warrant”). Each whole FT Warrant is exercisable into one (1) common share of the Company (each a “Share”) at an exercise price of C$0.40 for...

Vecima Networks Announces Upsize via Private Placement Financing

Written by Customer Service on December 10, 2022. Posted in Public Companies.

NOT FOR DISSEMINATION IN THE UNITED STATESOR THROUGH U.S. NEWSWIRE SERVICES VICTORIA, British Columbia, Dec. 09, 2022 (GLOBE NEWSWIRE) — Vecima Networks Inc. (“Vecima” or the “Company”) (TSX:VCM) is pleased to announce that due to significant demand, in addition to the offering for sale of up to 563,380 common shares (the “Common Shares”) in the capital of the Company as announced in a press release dated December 7, 2022 (the “LIFE Offering”), the Company has entered into an agreement with Raymond James Ltd. and Cormark Securities Inc. (together, the “Lead Agents”), as lead managers and joint book-runners, together with a syndicate of agents (collectively, with the Lead Agents, the “Agents”) pursuant to which the Lead Agents have agreed to offer for sale an additional 394,500 Common Shares at a price of $17.75 per Common Share...

Americas Technology Acquisition Corp. Announces Termination of Business Combination Agreement with Rally Communitas Corp. by Mutual Agreement

Written by Customer Service on December 10, 2022. Posted in Public Companies.

Dallas, TX, Dec. 09, 2022 (GLOBE NEWSWIRE) — Americas Technology Acquisition Corp. (NYSE: ATA, ATA.WS, ATA.U) (“ATA”), announced today that ATA and Rally Communitas Corp (“Rally”) have mutually agreed to terminate the previously announced Agreement and Plan of Merger (as amended, the “Merger Agreement”) between ATA and Rally. Termination of the Merger Agreement has been approved by the Board of Directors of both ATA and Rally. About Americas Technology Acquisition Corp. Americas Technology Acquisition Corp. is a blank check company organized for the purpose of effecting a merger, capital stock exchange, asset acquisition, or other similar business combination with one or more businesses or entities with an initial focus on technology, media, and telecommunications verticals. About Rally Rally is a Mass Mobility as a Service...

Imperial Announces up to $53 million Non-Brokered Private Placement of Debentures

Written by Customer Service on December 10, 2022. Posted in Public Companies.

VANCOUVER, British Columbia, Dec. 09, 2022 (GLOBE NEWSWIRE) — Imperial Metals Corporation (“Imperial” or the “Company”) (TSX:III) announces its intention to secure additional financing for ongoing operations at the Mount Polley mine and continued exploration and feasibility study work at the Red Chris mine by way of a non-brokered private placement of up to $53 million aggregate principal amount of non-convertible Debentures (the “Debentures”). The Debentures will have a 4 year term ending December 16, 2026. The Company intends to issue 6,625,000 warrants which will be exercisable into common shares of the Company at a price of $2.10, subject to all required shareholder and regulatory approvals. Interest at 10% per annum will be payable semi-annually in cash with the first payment due on June 16, 2023. Should the warrants not receive...

Arena Fortify Acquisition Corp. Obtains Stockholder Approval to Terminate Before Year-End

Written by Customer Service on December 10, 2022. Posted in Public Companies.

NEW YORK, New York, Dec. 09, 2022 (GLOBE NEWSWIRE) — Arena Fortify Acquisition Corp. (the “Company”) held a special meeting of stockholders on December 8, 2022, at 8:00 a.m., Eastern Time, as a completely virtual meeting, conducted over the internet via live audio webcast with no physical in-person meeting (the “Special Meeting”). At this Special Meeting, stockholders approved certain amendments (collectively, the “Charter Amendment”) to the Company’s amended and restated certificate of incorporation (the “Charter”) to, among other things, allow the Company to amend the date by which the Company must consummate a business combination from February 15, 2023 to December 9, 2022 (such date, the “Early Termination Date”). On December 8, 2022, following the Special Meeting, the Company filed the Charter Amendment with the Secretary...

Day: December 10, 2022